Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention
in adults who suffer from six or more migraine days per month. The study will enroll 690
patients across approximately 60 sites in the United States, Canada and Australia. Study
subjects will be divided evenly across a low dose group, a high dose group and a placebo
group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the
Company's novel injection paradigm.